큐라클

365270KOSDAQ자연과학 및 공학 연구개발업

46.8 / 100

Reference Date: 2026-06-10

Financial Score9.5 / 40

News Sentiment21.3 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR raises overvaluation concerns, Revenue is on a declining trend. Plunged 20.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Curacle is a biotech venture company developing innovative therapeutics targeting endothelial dysfunction, leveraging its proprietary platforms Solvadys and Eagles to advance first-in-class drug candidates such as CU06, CU71, and CU01. CU06, a retinal disease treatment, demonstrated vision improvement in Phase 2a trials, while collaborations with MapTics have expanded its antibody-based pipeline.

Number of Employees

31people

Average Salary

81.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

6.81Industry Average 3.240.0Point

2.1x industry avg (risky)

ROE

-54.03Industry Average -32.093.5Point

1.7x industry avg (good)

Debt Ratio

9.08Industry Average 7.312.0Point

Higher than industry avg (caution)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼91.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼25.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -40.6% (declining, 3yr)

Detailed News Sentiment

9 totalPositive 9Neutral 0Negative 0Average Sentiment Score 85

Positive
큐라클, 경상국립대와 업무협약 체결…공동연구 나서
큐라클이 경상국립대와의 업무협약을 통해 신약 개발 역량 강화에 긍정적 영향을 받을 것으로 예상됩니다.
Positive
큐라클, 경상국립대 약학대와 산학협력…오픈이노베이션 강화
큐라클의 경상국립대와의 산학협력 강화로 오픈 이노베이션 기반 신약 개발 역량이 향상될 것으로 기대됩니다.
Positive
큐라클, 신장병 치료제 임상서 단백뇨 최대 35.2% 감소 확인
큐라클의 신장질환 치료제 CU01 임상 결과, 단백뇨 감소 효과가 기대 이상으로 확인되어 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position5.0Point

52w mid range (48%)

Current 11,440Won52-week high 19,71052-week low 3,650

1-month return0.0Point

1m -20.39% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral[기재정정]투자판단관련주요경영사항 (이중항체 MT103 기술이전 계약 체결)2026-06-05
Neutral전환가액의조정 (제1회차)2026-05-28
Neutral분기보고서 (2026.03)2026-05-15